USH2242H1 - Light therapy system - Google Patents
Light therapy system Download PDFInfo
- Publication number
- USH2242H1 USH2242H1 US11/373,782 US37378206A USH2242H US H2242 H1 USH2242 H1 US H2242H1 US 37378206 A US37378206 A US 37378206A US H2242 H USH2242 H US H2242H
- Authority
- US
- United States
- Prior art keywords
- grt
- diodes
- lite
- mode
- light emitting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001126 phototherapy Methods 0.000 title description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 abstract description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 7
- 210000000707 wrist Anatomy 0.000 description 7
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000000881 depressing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- 206010028836 Neck pain Diseases 0.000 description 2
- 208000007613 Shoulder Pain Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 208000037975 work-related injury Diseases 0.000 description 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000011074 autoclave method Methods 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0644—Handheld applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
Definitions
- the GRT LITE Model PRO-8 A is substantially equivalent to other pulsed therapeutic light therapy systems currently in commercial distribution.
- the Model PRO-8A has the same intended use and similar technological characteristics to predicate devices. It combines the clinically accepted therapeutic uses of several previously FDA 510(k) approved light therapy systems currently in commercial distribution into one compact system.
- the technological equivalence to the predicate devices is substantiated by the wavelength and power output generated by the Model PRO-8A.
- the Model PRO-8A will provide the same treatment benefits and regimens for clinical presentations already approved by the Food and Drug Administration for the predicate devices.
- Predicate Device 510(k) if Manufacturer Tuco Erchonia PL3000 KO 12580 Tuco Innovations Excalibur System K041530 Stargate International, Inc. Microlight 830 Laser K010175 Microlight Corporation of America Acculaser Pro LLLT K020657 Acculaser, Inc. Device
- the GRT LITE Model PRO-8A is a non-heating lamp, infrared as described under the provisions of 21CFR ⁇ 890.5500 and is clinically indicated for:
- Adjunctive use in providing temporary relief of minor chronic neck and shoulder pain of nisculoskeletal origin in providing temporary relief of minor chronic neck and shoulder pain of nisculoskeletal origin.
- CTS Carpal Tunnel Syndrome
- pain therapy treatment can be prescribed for pain associated with the clinical presentations specified above by having the beams pulsed or continuous with time considerations.
- the GRT LITE Model PRO-8A's variables conform to the performance specifications of the clinical parameters used by the predicate devices in wavelength, frequency as a function of time, and power output.
- FIG. 1 is a top and end view of the GRT light apparatus
- FIG. 2 is an exploded perspective and machine drawing views of the housing of the GRT light apparatus.
- FIG. 3 is an illustration of a human hand indicating treatment points in accordance with the invention.
- the Model PRO-8A is a hand-held, non-invasive, pain therapy system which utilizes four nonheating light emitting diodes (LED) consisting of two visible LED's and two infrared LED's in one system, It combines the clinically accepted therapeutic treatment of numerous predicate light therapy systems currently in commercial distribution and 510(k) approved.
- LED light emitting diodes
- the system consists of a basic hand-held, battery operated, control unit with the four LED's emitting light through a special red acrylic lens which does not absorb any light transmission.
- the visible LEDs operate at a measured wavelength of 628 nm ( ⁇ 5%) and the infrared LEDs operate at a measured wavelength of 850 nm ( ⁇ 5%),
- the Model PRO-8A complies with all performance, labeling, and manufacturing standards set forth in 21 CFR.
- the GRT LITE Model PRO-8A and the aforementioned predicate devices emit visible and invisible photonic energy to human tissue.
- the comparing of the technologies is dependent on the laws of physics in that the variables are frequency, wavelength, power output, and time.
- the testing of the Model PRO-8A includes functional performance, electrical safety, and component specification verification This includes an eight-stage manufacturing testing and verification GRT Solutions, Inc. procedure protocol that is tracked by run component and system serial number.
- Model PRO-8A The operation of the Model PRO-8A is controlled using PROM technology. Once the CPU is programmed, the “hard software” cannot be changed or altered. This hard software affords the operator six different selection options for the Model PRO-8A operating modes. Each of the six operating modes have specific operating frequencies (pulsed or continuous), and visible and infrared light combinations of LED operation. One visible LED is always on, regardless of mode selection, indicating power to the system is on. Every system is checked and tracked, by serial number, for correct diode performance, all six mode operation parameters as they relate to the specific diode, power output, and total operating time.
- the GRT LITE Model PRO-8A 10 includes operating controls consisting of six (6) user choice mode of operation controls and four (4) light emitting diodes (LEDs) 12 , 14 , 16 , and 18 contained within housing 20. Two of the LEDs are in the visible light spectrum and flank two (2) LEDs which are in the infrared light spectrum. All four diodes transmit through a special red polymer lens 2 2 ; which is custom designed and manufactured from a non-absorption of light transmission acrylic material.
- LEDs light emitting diodes
- the “visible” LEDs (VI & V4) operate at a wavelength (A) of 628 nm ( ⁇ 5%)—measured.
- the “Infrared” LEDs (1-2 & 13) operate at a wavelength (A) of 850 nm ( ⁇ 5%)—measured.
- the six individual control switches allows for six separate modes of operation of the four LEDs.
- Mode “1” a pulsed frequency mode with all four diodes operating at different frequencies with all automatically shutting off after 15 minutes:
- Mode “2” a pulsed frequency mode with all four diodes operating at different frequencies with all automatically shutting off after 15 minutes:
- Mode “4” a pulsed frequency mode with all four diodes operating at different frequencies with all automatically shutting off after 15 minutes:
- Mode “R” a continuous mode at with both visible diodes continuously operating and both infrared diodes “Off,” both automatically shutting off after 15 minutes:
- Mode “I” a continuous mode at with both infrared diodes continuously operating, one visible diode is “Off,” and 1 visible diode operating at 2.0 Hz and serves as a visual indicator the system is running, all three automatically shutting off after 15 minutes:
- the device is controlled using PROM technology. Once programmed, the “hard software” cannot be changed and/or altered and any changes and/or modifications would require a different chip.
- One visible LED is always on, regardless of mode selection, indicating power to the system is on.
- the device can only be powered “ON” by depressing any of the six (6) control switches (buttons).
- the system can be powered “OFF” depressing any of the six (6) control switches (buttons),
- Software/Firmware The system uses PROM technology employing firmware or what is also referred to as “hard software.” The specific component CPU used can only be programmed one time and cannot be modified. Should any interruption of the program occur, the system will automatically shut off. The software provides a low battery indication and will not operate with any AC power source.
- LEDs light emitting diodes
- NSR non-significant risk
- FDA Food and Drug Administration
- FDA Federal and Drug Administration
- CER Code of Federal Regulations
- MDUF Medical Device User Fee Cover Sheet
- GRT Solutions, Inc. is required to adhere to what the FDA defines as “Good Manufacturing Practices.”
- the FDA has the authority to inspect any or all GRT Solutions' owned entities involved in the manufacturing and distribution of the device. This includes, but is not limited to, quality control, testing, etc., etc.
- the itemization contained in the GRT Assembly Manual exceeds this requirement.
- the GRT LITE Model PRO-8AS is classified as a Class II Medical Device. It is regulated by the provisions of 21 CFR 890.5500 as an “infrared lamp.” It also will be classified under a specific product code, i.e., “NHN,” The device carries an “NSR” rating indicating it has “Non Significant Risk” to the user and/or patient.
- FCC Federal Communications Commission
- FCC Federal Communications Commission
- GRT LITE Model PRO-8A design incorporates that consideration and meets the standard called for under Rules and Regulations, Title 47, Part 15 Subpart B.
- Occupational Safety and Health Administration There are no anticipated risk of work-related injury (repetitive or otherwise) and/or illness to any GRT Solutions, Inc employee in the execution of their employee duties after the first 1,000 units are produced.
- the first 1,000 units call for a soldering station and will be implemented according to OSHA standards and requirements.
- the GRT Assembly Process Manual was developed to insure worker training and safety, and in the unlikely event of a work-related injury, GRT Solutions can comply with all OSHA reporting requirements.
- Wavelength This is the measurement of the light concentration arid is expressed in nanometers (nm). This metric measurement means each nanometer 900 equals I billionth of a meter or 1/25,400.000 of an inch.
- the technology involved with light therapy uses wavelengths from the visible spectrum of 380-760 nm to the near infrared spectrum which is greater than 760 nm. These are ranges/spectrums well away from the damaging spectrums of lower 600 wavelengths of ultraviolet, and the higher wavelengths of x-rays, gamma and cosmic rays.
- the GRT LITE's range is from 600 nm to 900 nm depending on the mode selected.
- Power Output This is the measurement of the light concentration expressed in watts per centimeter squared (W/cm 2 ).
- the GRT LITE operates at ⁇ 22W/cm 2 depending on the mode(s) selected.
- Frequency This is the measurement of the amount of time the light is activated and is expressed in “Hertz (Hz)” which is equal to one cycle per second. For example, if the system is operating at a frequency of 400 Hz that means the pulsed mode of that system has each second broken down into a total of 800 cycles. This translates to the system powering the diodes “ON - 400 times a second” and not powering the diodes, or “OFF - 400 times a second:”
- Step 1 Decide which of the six modes you want the GRT-LITE SYSTEM to operate in.
- the different modes are programmed at the factory and are set according to the following:
- Step 2 Depress the desired “Mode” button, for one-half second and execute the clinical procedure. Depress the “Mode” button, for one-half second to shut the system off Depressing any “Mode” button will turn the system off.
- Step 1 Patient Evaluation: A proper evaluation of the cervical and shoulder areas should consist of measurements of the patient's range of motion before and after treatment and the evaluation of the pain level.
- Step 2 Depress the “Mode R” button on the GRT-LITE.
- Step 3 Apply light starting in the cerebral region, at the top of the ear, illuminating the left cervical anterior and posterior muscles, working the light down into the left shoulder and torso anterior and posterior muscles. Keep the head of the GRT LITE 1 ⁇ 2′′ to 3 ⁇ 4′′ from the skin's surface.
- Step 4 Repeat Step 3 to right cervical shoulder and torso area.
- Step 5 One minute of “Mode R” should be applied to right shoulder during passive external rotation of the shoulder. Cover the anterior muscles of the right shoulder (pectoralis group) with the patient's arm bent at the elbow.
- Step 6 One minute of “Mode R” applied to the right shoulder during passive adduction of patients right arm and shoulder. Cover the posterior muscles of the right shoulder.
- Step 7 One minute of “Mode R” applied to the right cervical muscle and trapezius muscle during passive left lateral flexion of the cervical spine. Starting in the neutral position of the head, applies beams to the right cervical muscles and right trapezius muscles.
- Step 8 One minute of “Mode R” to the right sternocleidomastold and scalene muscles during passive range of motion. Apply beams to the right sternocteidomastoid and scalenus muscles.
- Step 9 Repeat step 5 to the left shoulder.
- Step 10 Repeat step 6 to the left shoulder.
- Step 11 Repeat step 7 to the left cervical spine.
- Step 12 Repeat step 8 to the right cervical spine.
- the GRT-LITE can be used in either the pulsed or continuous mode to apply this protocol's required energy levels (joules).
- Direct beams on the radial side of wrist at the proximal wrist crease are Direct beams on the radial side of wrist at the proximal wrist crease.
- the practitioner can re-evaluate the patients wrist range of motion noting any changes. They can also note any changes in patient's ability to tolerate pain.
- the GRT LITE has been designed so that there is no maintenance required by the user other than keeping the GRT LITE clean, stored in the proper environment, and battery replacement (see Quick Reference Card).
- each diode is in excess of 100,000 clinical applications to minimize failure during the life of the product. Any rare failure of the (visible red diodes Dl or 04) will be obvious, as they will not illuminate when the system is powered on. If you suspect one of the (invisible infrared diodes 02 or 03) has inexplicably failed you can check them performing the following test procedures:
- the GRT LITE . . . can not be sterilized by any liquid or autoclave method
- the user may remove dirt, dust and oils by wiping the GRT LITE clean with a dry cloth. Cleaning should be limited to wiping the GRT LITE clean.
- the red lens covering the four diodes should be cleaned using the following steps:
- the lens can be cleaned using a Q-TipTM type cotton swab dipped in alcohol.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
An apparatus for treating musculoskeletal disorders comprises a plurality of light emitting diodes and a control circuit. The control circuit causes the light emitting diodes to pulse at predetermined frequencies of from 0 (continuous) to 125 Hz. The light emitting diodes themselves emit light radiation in a frequency range of 628 nanometers (+/− 5%) for the visible diodes and 850 nanometers (+/− 5%) for the infrared diodes.
Description
This application claims benefit of priority of U.S. provisional application number 60/774,454 filed on Feb. 17, 2006.
The GRT LITE Model PRO-8 A is substantially equivalent to other pulsed therapeutic light therapy systems currently in commercial distribution. The Model PRO-8A has the same intended use and similar technological characteristics to predicate devices. It combines the clinically accepted therapeutic uses of several previously FDA 510(k) approved light therapy systems currently in commercial distribution into one compact system.
The technological equivalence to the predicate devices is substantiated by the wavelength and power output generated by the Model PRO-8A. The Model PRO-8A will provide the same treatment benefits and regimens for clinical presentations already approved by the Food and Drug Administration for the predicate devices.
The predicate devices the Model PRO-8A establishes equivalence to include:
Predicate Device | 510(k) if | Manufacturer |
Tuco Erchonia PL3000 | KO 12580 | Tuco Innovations |
Excalibur System | K041530 | Stargate International, Inc. |
Microlight 830 Laser | K010175 | Microlight Corporation of America |
Acculaser Pro LLLT | K020657 | Acculaser, Inc. |
Device | ||
The GRT LITE Model PRO-8A is a non-heating lamp, infrared as described under the provisions of 21CFR §890.5500 and is clinically indicated for:
Adjunctive use in providing temporary relief of minor chronic neck and shoulder pain of nisculoskeletal origin.
Adjunctive use in providing temporary relief of minor chronic pain associated with Carpal Tunnel Syndrome (CTS).
As with the predicate devices, pain therapy treatment can be prescribed for pain associated with the clinical presentations specified above by having the beams pulsed or continuous with time considerations. The GRT LITE Model PRO-8A's variables conform to the performance specifications of the clinical parameters used by the predicate devices in wavelength, frequency as a function of time, and power output.
The Model PRO-8A is a hand-held, non-invasive, pain therapy system which utilizes four nonheating light emitting diodes (LED) consisting of two visible LED's and two infrared LED's in one system, It combines the clinically accepted therapeutic treatment of numerous predicate light therapy systems currently in commercial distribution and 510(k) approved.
The system consists of a basic hand-held, battery operated, control unit with the four LED's emitting light through a special red acrylic lens which does not absorb any light transmission. The visible LEDs operate at a measured wavelength of 628 nm (±5%) and the infrared LEDs operate at a measured wavelength of 850 nm (±5%), The Model PRO-8A complies with all performance, labeling, and manufacturing standards set forth in 21 CFR.
The GRT LITE Model PRO-8A and the aforementioned predicate devices emit visible and invisible photonic energy to human tissue. The comparing of the technologies is dependent on the laws of physics in that the variables are frequency, wavelength, power output, and time.
The performance parameters and intended use of the GRT LITE Model PRO-8A are identical to all predicate devices and conforms with all FDA approved application protocols for the devices.
The testing of the Model PRO-8A includes functional performance, electrical safety, and component specification verification This includes an eight-stage manufacturing testing and verification GRT Solutions, Inc. procedure protocol that is tracked by run component and system serial number.
The operation of the Model PRO-8A is controlled using PROM technology. Once the CPU is programmed, the “hard software” cannot be changed or altered. This hard software affords the operator six different selection options for the Model PRO-8A operating modes. Each of the six operating modes have specific operating frequencies (pulsed or continuous), and visible and infrared light combinations of LED operation. One visible LED is always on, regardless of mode selection, indicating power to the system is on. Every system is checked and tracked, by serial number, for correct diode performance, all six mode operation parameters as they relate to the specific diode, power output, and total operating time.
As shown in FIGS. 1 and 2 , the GRT LITE Model PRO-8A 10 includes operating controls consisting of six (6) user choice mode of operation controls and four (4) light emitting diodes (LEDs) 12, 14, 16, and 18 contained within housing 20. Two of the LEDs are in the visible light spectrum and flank two (2) LEDs which are in the infrared light spectrum. All four diodes transmit through a special red polymer lens 22; which is custom designed and manufactured from a non-absorption of light transmission acrylic material.
The “visible” LEDs (VI & V4) operate at a wavelength (A) of 628 nm (±5%)—measured.
The “Infrared” LEDs (1-2 & 13) operate at a wavelength (A) of 850 nm (±5%)—measured.
The six individual control switches allows for six separate modes of operation of the four LEDs.
Mode “1” a pulsed frequency mode with all four diodes operating at different frequencies with all automatically shutting off after 15 minutes:
-
- VI 3.0 Hz
- 12 13.0 Hz
13 93.0 Hz - V4 7.0 Hz
Mode “2” a pulsed frequency mode with all four diodes operating at different frequencies with all automatically shutting off after 15 minutes:
-
- VI 8.0 Hz
- 12 31.0 Hz
- 13 81.0 Hz
- V4 38.0 Hz
- Mode “3” a pulsed frequency mode with all four diodes operating at different frequencies with all automatically shutting off after 15 minutes:
- VI 2.0 Hz
- 12 125.0 Hz
- 13 45.0 Hz
- V4 10.0 Hz
Mode “4” a pulsed frequency mode with all four diodes operating at different frequencies with all automatically shutting off after 15 minutes:
-
- V1 33.0 Hz
- 12 8.0 Hz
- 13 5.0 Hz
- V4 22.0 Hz
Mode “R” a continuous mode at with both visible diodes continuously operating and both infrared diodes “Off,” both automatically shutting off after 15 minutes:
-
- V1 Continuous
- 12 Off
- 13 Off
- V4 Continuous
Mode “I” a continuous mode at with both infrared diodes continuously operating, one visible diode is “Off,” and 1 visible diode operating at 2.0 Hz and serves as a visual indicator the system is running, all three automatically shutting off after 15 minutes:
-
- V1 Off
- 12 Continuous
- 13 Continuous
- V4 2.0 Hz
The device is controlled using PROM technology. Once programmed, the “hard software” cannot be changed and/or altered and any changes and/or modifications would require a different chip. One visible LED is always on, regardless of mode selection, indicating power to the system is on.
The device can only be powered “ON” by depressing any of the six (6) control switches (buttons). The system can be powered “OFF” depressing any of the six (6) control switches (buttons),
The specifications are as follows:
Voltage: | Operating voltage: 1.6 v-4.6 v |
Power: | 150 Ma |
Safety: | Chassis-to-ground risk current 0 μA |
Other: | FCC Standard - 47 CFR Part 15B |
All Electrical Components Utilized Are UL ® | |
Approved | |
System including batteries: 4.97 oz (141.1 gms) | |
Dimensions: | 4.344″ × 2.376″ × 1.100″ |
(110.338 mm × 60.198 mm × 27.94 mm) | |
Diodes: | Two Visible light LEDs |
Two Infrared light LEDs | |
Power: | Maximum power output all diodes: ≦25.0 mwcm2 |
Wavelength: | Visible light LEDs - 628 nm (±5%) measured |
Two Infrared light LEDs - 850 nm (±5%) measured | |
Temperature: | 10° C. to 40° C. operating, −20° C. to 50° C. |
storage. If system stored below 40° F., allow system | |
to warm up to room temperature before use | |
Humidity: | 15% to 90% noncondensing |
Altitude: | Operational capability beyond MMI standard of |
−500 to +5000 feet elevational barometric pressures | |
Impact: | Constructed to satisfy pre-shipment test standards of |
National Safe Transit Association, Document 2.4 | |
Battery: | Rechargeable batteries - 2 ea size “AA” NiMh - |
2200 mAh - replaceable | |
VISIBLE DIODES: | |
Diodes: | Two each light emitting diodes |
Maximum power output per diode: ≦4.5 mw; | |
diffuse beams | |
Wavelength: | 628 nm (±5%) measured |
Safety: | Chassis-to-ground risk current during operation: |
0 μA | |
Color: | Red |
Temperature: | 10° C. to 40° C. operating, −20° C. to 50° C. |
storage. | |
Humidity: | 15% to 90% noncondensing. |
INFRARED | |
DIODES: | |
Diodes: | Two each infrared light emitting diodes |
Power: | Maximum power output per diode: ≦7.0 mw; |
Diffuse beams | |
Wavelength: | 850 nm (±5%) measured |
Safety: | Chassis-to-ground risk current during operation: |
0 μA | |
Color: | Clear |
Temperature: | 10° C. to 40° C. operating, −20° C. to 50° C. |
storage | |
Humidity: | 15% to 90% noncondensing |
LENS: | |
Forming | 300° F. (149° C.) |
Temperature: | |
Refractive Index: | 1.49 |
Light Transmission: | ≧98% |
PH: | None |
Color: | Red |
Specific Gravity: | 1.1 to 1.2 |
Composition: | P(MMA) Proprietary 99-100% |
Methyl methacrylate <1% | |
Chemical Family: | Acrylic Copolymer |
Output | Wave- | Regulation | Product | Product | ||
Device | Manufacturer | Power* | length | Number | Code | Nomenclature |
Present | GRT | ≦4.5 | 628 nm | 21 CFR | NHN | Lamp, Infared |
Invention | Solutions, Inc. | mwcm2 | §890.5500 | |||
Model | ≦7.0 | 850 nm | ||||
8-A | mwcm2 | |||||
* = per diode |
Identification/Classification—21 CFR §890.5500—A device that emits energy at infrared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.
Product | |||||
Wave- | Regulation | Product | Nomen- | ||
Device | Manufacturer | length | Number | Code | clature |
Erchonia | TUCO | 630 nm | 21 CFR | NHN | Lamp, |
Innovations | §890.5500 | Infared | |||
PL3000 | |||||
KL12580 | |||||
Identification/Classification—21 CFR §890.5500—A device that emits energy at infrared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.
Product | |||||
Wave- | Regulation | Product | Nomen- | ||
Device | Manufacturer | length | Number | Code | clature |
Excalibur | TUCO | ≦5 | 21 CFR | NHN | Lamp, |
Light | Innovations | mwcm2 | §890.5500 | Infared | |
Therapy | |||||
System | |||||
K041530 | |||||
Identification/Classification:—21 CFR §890.5500 A device that emits energy at infrared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.
Product | |||||
Wave- | Regulation | Product | Nomen- | ||
Device | Manufacturer | length | Number | Code | clature |
Microlight | Microlight | 830 nm | 21 CFR | NHN | Lamp, |
830 | Corporation of | §890.5500 | Infared | ||
America | |||||
Laser | |||||
System | |||||
K010175 | |||||
Identification/Classification—21 CFR §890.5500—A device that emits energy at infared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.
Product | |||||
Wave- | Regulation | Product | Nomen- | ||
Device | Manufacturer | length | Number | Code | clature |
Acculasser | Acculasser, | 830 nm | 21 CFR | NHN | Lamp, |
PRO | Inc. | §890.5500 | Infared | ||
Low LLT | |||||
Dev. | |||||
K020657 | |||||
Identification/Classification—21 CFR §890.5500—A device that emits energy at infared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.
Software/Firmware—The system uses PROM technology employing firmware or what is also referred to as “hard software.” The specific component CPU used can only be programmed one time and cannot be modified. Should any interruption of the program occur, the system will automatically shut off. The software provides a low battery indication and will not operate with any AC power source.
Personal Injury—There are no known risk for any type of personal injury that can be generated by the GRT LITE Model 8-A The system uses light emitting diodes (LEDs) as its energy source which have not proven to be damaging to human tissue. The Food and Drug Administration does not classify this device as a radiation emitting device and is considered a “non-significant risk” (NSR) device. In the infrared mode(s), the LEDs do not carry the high potential for injury to the eye as do infrared lasers used by other substantially equivalent devices. Regardless, the system still carries a clear “Warning Label” informing the user not to look directly into the light.
Operational Safety—There are no potential operational safety issues associated with the GRT LITE. This includes no known potential risk to the clinical operator and/or patient.
Regulatory Compliance Considerations
Food and Drug Administration (FDA)—The United States Food and Drug Administration (FDA) is the primary regulatory body covering the GRT LITE Model PRO-8A. Under the provisions of Title 21; U.S.C. and 21 Code of Federal Regulations (CER) both the corporation and the product must meet certain standards and comply with specific regulations:
Initial Registration of Device Establishment—This requirement was met by the filing of FDA Form 2891 on Jan. 27, 2005. It is the corporation's responsibility to report any changes and/or additions to the FDA. The FDA will issue an Owner/Operator Number to GRT Solutions, Inc. upon their completion of the processing of the form. (9070001)
Device Listing—All medical devices sold and distributed within the United States and its territories are required to be registered with the FDA. GRT Solutions, Inc. classification will be that of a “Repackager/Relabeler.” This requirement was met by the filing of FDA Form 2892 on Jan. 27, 2005 (E214727).
FDA Approval to Market the GRT LITE Model PRO-8A—GRT Solutions, Inc. is required to file, and have approved by the FDA, what is called a “510(k) Application.” This a notification of the corporation's intent to market the GRT LITE Model PRO-8A in the United States as a “substantially equivalent device” to other light therapy systems already approved to be marketed by the FDA. This filing/application must be approved by the FDA prior to marketing the GRT LITE Model PRO-8A. Although the user of the Model PRO-8A can decide which clinical protocol to utilize, GRT Solutions, Inc. is limited to presenting only the usage approved by the FDA in all its literature and/or operation instructions. We will be required to limit our marketing efforts to the FDA approved utilization applied for which is:
-
- Adjunctive use in providing temporary relief of minor chronic neck and shoulder pain of musculoskeleral origin.
- Adjunctive use in providing temporary relief of minor chronic pain from Carpal Tunnel Syndrome (CTS).
Medical Device User Fee Cover Sheet (MDUF)—This submission requires the payment of a fee to the FDA prior to the filing of the 510(k) application through FDA Form 3601. This requirement was met and carries the identification number of 017070-956733.
Good Manufacturing Practices—GRT Solutions, Inc. is required to adhere to what the FDA defines as “Good Manufacturing Practices.” The FDA has the authority to inspect any or all GRT Solutions' owned entities involved in the manufacturing and distribution of the device. This includes, but is not limited to, quality control, testing, etc., etc. The itemization contained in the GRT Assembly Manual exceeds this requirement.
FDA Regulations (General)—The GRT LITE Model PRO-8AS is classified as a Class II Medical Device. It is regulated by the provisions of 21 CFR 890.5500 as an “infrared lamp.” It also will be classified under a specific product code, i.e., “NHN,” The device carries an “NSR” rating indicating it has “Non Significant Risk” to the user and/or patient.
Federal Communications Commission (FCC)—All commercial electronic devices (unintentional radio-frequency radiators) destined for sale in the United States that have clocks/oscillators that operate at a frequency of greater than 9 kHz and use digital techniques are regulated by the Federal Communications Commission (FCC) under Rules and Regulations, Title 47, Part 15 Subpart B. The GRT LITE Model PRO-8A design incorporates that consideration and meets the standard called for under Rules and Regulations, Title 47, Part 15 Subpart B.
State of California Department of Health Services/Food and Drug Branch—Since GRT Solutions, Inc. will operate in the state of California, the corporation is required to file a Medical Device Licensing Application with this entity and pay a licensing fee.
Occupational Safety and Health Administration (OSHA)—There are no anticipated risk of work-related injury (repetitive or otherwise) and/or illness to any GRT Solutions, Inc employee in the execution of their employee duties after the first 1,000 units are produced. Currently, the first 1,000 units call for a soldering station and will be implemented according to OSHA standards and requirements. The GRT Assembly Process Manual was developed to insure worker training and safety, and in the unlikely event of a work-related injury, GRT Solutions can comply with all OSHA reporting requirements.
In order to clarify how light affects the body, one needs to have an understanding of the basic physics involved. The three most relevant measurements for all systems (LED or Laser) are expressed in “wavelength”—“power output”—“frequency,”
Wavelength—This is the measurement of the light concentration arid is expressed in nanometers (nm). This metric measurement means each nanometer 900 equals I billionth of a meter or 1/25,400.000 of an inch. The technology involved with light therapy uses wavelengths from the visible spectrum of 380-760 nm to the near infrared spectrum which is greater than 760 nm. These are ranges/spectrums well away from the damaging spectrums of lower 600 wavelengths of ultraviolet, and the higher wavelengths of x-rays, gamma and cosmic rays. The GRT LITE's range is from 600 nm to 900 nm depending on the mode selected.
Power Output—This is the measurement of the light concentration expressed in watts per centimeter squared (W/cm2). The GRT LITE operates at ≦22W/cm2 depending on the mode(s) selected.
Frequency—This is the measurement of the amount of time the light is activated and is expressed in “Hertz (Hz)” which is equal to one cycle per second. For example, if the system is operating at a frequency of 400 Hz that means the pulsed mode of that system has each second broken down into a total of 800 cycles. This translates to the system powering the diodes “ON - 400 times a second” and not powering the diodes, or “OFF - 400 times a second:”
To operate the GRT LITE requires ONLY two (2) very simple steps:
Red | Infrared | Infrared | Red | ||
D-1 | D-2 | D-3 | D-4 | Run | |
Mode | Freq. | Freq. | Freq. | Freq. | |
1 | 3 Hz | 13 Hz | 93 Hz | 7 Hz | Auto |
OFF @ | |||||
15 min. | |||||
2 | 8 Hz | 31 Hz | 81 Hz | 38 Hz | Auto |
OFF @ | |||||
15 min. | |||||
3 | 2 Hz | 125 Hz | 45 Hz | 10 Hz | Auto |
OFF @ | |||||
15 min. | |||||
4 | 33 Hz | 8 Hz | 5 Hz | 22 Hz | Auto |
OFF @ | |||||
15 min. | |||||
R | Continuous | Off | Off | Continuous | Auto |
OFF @ | |||||
15 min. | |||||
I | Off | Continuous | Continuous | 2 Hz | Auto |
OFF @ | |||||
15 min. | |||||
-
- Note: The GRT-LITE will not operate if the battery levels are too low. We recommend changing batteries after 12-14 hours or two days use . . . whichever comes first.
Step 5—One minute of “Mode R” should be applied to right shoulder during passive external rotation of the shoulder. Cover the anterior muscles of the right shoulder (pectoralis group) with the patient's arm bent at the elbow.
-
- NOTE: Whenever the word passive is used move the patient's appendage (head and/or shoulder) only as necessary to gain access with the light.
Step 6—One minute of “Mode R” applied to the right shoulder during passive adduction of patients right arm and shoulder. Cover the posterior muscles of the right shoulder.
Step 7—One minute of “Mode R” applied to the right cervical muscle and trapezius muscle during passive left lateral flexion of the cervical spine. Starting in the neutral position of the head, applies beams to the right cervical muscles and right trapezius muscles.
Step 8—One minute of “Mode R” to the right sternocleidomastold and scalene muscles during passive range of motion. Apply beams to the right sternocteidomastoid and scalenus muscles.
Step 9—Repeat step 5 to the left shoulder.
Step 10—Repeat step 6 to the left shoulder.
Step 11—Repeat step 7 to the left cervical spine.
FDA Approved CTS Treatment Protocol
Depress the “Mode I” button on the GRT-LITE.
The GRT-LITE can be used in either the pulsed or continuous mode to apply this protocol's required energy levels (joules).
Continuous Mode: Use “Mode I”
As shown in FIG. 3 , apply light beams to the four treatment points 1, 2, 3 and 4 indicated in the picture to the right using the technique below. Use the flashing “red” beam as a placement guide.
Scan across the ulnar muscle between the Radial longitudinal crease and the proximal thumb joint.
Direct beams on the radial side of wrist at the proximal wrist crease.
Direct beams to the middle of the wrist at the proximal wrist crease across the carpal ligament.
Direct beams to the ulnar side of the wrist at the proximal crease across the carpal ligament.
Repeat the direction of the beams to the ulnar side of the wrist at the proximal crease across the carpal ligament.
Following the treatment the practitioner can re-evaluate the patients wrist range of motion noting any changes. They can also note any changes in patient's ability to tolerate pain.
The GRT LITE has been designed so that there is no maintenance required by the user other than keeping the GRT LITE clean, stored in the proper environment, and battery replacement (see Quick Reference Card).
The designed operating life of each diode is in excess of 100,000 clinical applications to minimize failure during the life of the product. Any rare failure of the (visible red diodes Dl or 04) will be obvious, as they will not illuminate when the system is powered on. If you suspect one of the (invisible infrared diodes 02 or 03) has inexplicably failed you can check them performing the following test procedures:
Using a standard digital camera with an LCD screen, or a digital camcorder, depress the “I” control and look through the viewer at the top of the system. Both 02 and 03 will emit a “bright” glow; 04 will flash two times per second. This verifies the GRT LITE is working properly.
All repair and/or service to GRT LITE must be done by an authorized GRT SOLUTIONS facility or service center. Any disassembling of the system immediately voids the warranty.
Dirt, dust, moisture and oils from the human body may settle on the system. These can distort the beams by clouding the lenses and may affect clinical performance. Regardless, the GRT LITE . . . can not be sterilized by any liquid or autoclave method
Routine Cleaning
The user may remove dirt, dust and oils by wiping the GRT LITE clean with a dry cloth. Cleaning should be limited to wiping the GRT LITE clean. The red lens covering the four diodes should be cleaned using the following steps:
Blow the system clean using a compressed air aerosol the type used to clean computers and electronics.
Wipe the red lens with a standard alcohol swab.
The lens can be cleaned using a Q-Tip™ type cotton swab dipped in alcohol.
Repeat aerosol spray making sure system is completely dry.
Inspect the unit before each use or after changing the batteries. Clean system at least weekly after every five patients.
Claims (1)
1. Therapeutic apparatus comprising:
a housing
a plurality of light emitting diodes within said housing;
a transparent lens covering said light emitting diodes; and
a control circuit having an embedded program for selectively activating and deactivating said light emitting diodes;
said plurality of light emitting diodes comprising at least one visible light emitting diode and at least one infrared diode transmitting in a frequency range of between 845 to 855 nanometers and pulsing at a range of less than 125 Hz.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/373,782 USH2242H1 (en) | 2006-02-17 | 2006-03-09 | Light therapy system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77445406P | 2006-02-17 | 2006-02-17 | |
US11/373,782 USH2242H1 (en) | 2006-02-17 | 2006-03-09 | Light therapy system |
Publications (2)
Publication Number | Publication Date |
---|---|
US20090234424A1 US20090234424A1 (en) | 2009-09-17 |
USH2242H1 true USH2242H1 (en) | 2010-07-06 |
Family
ID=41063882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/373,782 Abandoned USH2242H1 (en) | 2006-02-17 | 2006-03-09 | Light therapy system |
Country Status (1)
Country | Link |
---|---|
US (1) | USH2242H1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9352170B1 (en) | 2012-01-31 | 2016-05-31 | Christina Davis | Spectral light therapy for autism spectral disorders |
US9901747B2 (en) | 2015-04-10 | 2018-02-27 | Clarify Medical Inc. | Phototherapy light engine |
US11583695B2 (en) | 2014-02-03 | 2023-02-21 | Zerigo Health, Inc. | Systems and methods for phototherapy |
US11638834B2 (en) | 2015-07-24 | 2023-05-02 | Zerigo Health, Inc. | Systems and methods for phototherapy control |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6663659B2 (en) * | 2000-01-13 | 2003-12-16 | Mcdaniel David H. | Method and apparatus for the photomodulation of living cells |
-
2006
- 2006-03-09 US US11/373,782 patent/USH2242H1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6663659B2 (en) * | 2000-01-13 | 2003-12-16 | Mcdaniel David H. | Method and apparatus for the photomodulation of living cells |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9352170B1 (en) | 2012-01-31 | 2016-05-31 | Christina Davis | Spectral light therapy for autism spectral disorders |
US11583695B2 (en) | 2014-02-03 | 2023-02-21 | Zerigo Health, Inc. | Systems and methods for phototherapy |
US9901747B2 (en) | 2015-04-10 | 2018-02-27 | Clarify Medical Inc. | Phototherapy light engine |
US11786748B2 (en) | 2015-04-10 | 2023-10-17 | Zerigo Health, Inc. | Phototherapy light engine |
US11638834B2 (en) | 2015-07-24 | 2023-05-02 | Zerigo Health, Inc. | Systems and methods for phototherapy control |
Also Published As
Publication number | Publication date |
---|---|
US20090234424A1 (en) | 2009-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12070416B2 (en) | Systems and methods for the treatment of eye conditions | |
JP6927881B2 (en) | Systems and methods for treating eye disorders | |
US20190091065A1 (en) | Systems and Methods For the Treatment of Eye Conditions | |
AU2010280362B2 (en) | Handheld low-level laser therapy apparatus | |
USH2242H1 (en) | Light therapy system | |
Fluent et al. | Shedding light on a potential hazard: Dental light-curing units | |
US20070219600A1 (en) | Devices and methods for targeted nasal phototherapy | |
Price et al. | The dental curing light: a potential health risk | |
Lawrence et al. | Estimating the costs of non-fatal consumer product injuries in the United States | |
CN111107781B (en) | Ophthalmoscope using natural pupil dilation | |
Landry et al. | Retinal phototoxicity: a review of standard methodology for evaluating retinal optical radiation hazards | |
Fleischer Jr et al. | Tanning facility compliance with state and federal regulations in North Carolina: a poor performance | |
Reidenbach | Results from two research projects concerning aversion responses | |
Carniol et al. | Clinical procedures in laser skin rejuvenation | |
Bertolini et al. | Attenuation assessment of medical protective eyewear: the AVEN experience | |
Moseley et al. | Biomedical Laser Safety | |
Gaffar et al. | Identifying and Mitigating Design Challenges of Ophthalmology Tele-medicine at Mayo Clinic | |
CN221084444U (en) | Vision eye protection instrument with multiple light power protection | |
Smalley | Laser safety: regulations, standards, and guidelines for practice | |
Reidenbach | Results of Investigations on the Blink Reflex as a Protective Means Against Laser and LED Radiation: A Description Based on Fundamental Psychophysical Laws | |
Ediger et al. | Optical radiation safety considerations for ocular glucose monitoring | |
MICHAELSON | Standards for protection of personnel against nonionizing radiation | |
US20200078219A1 (en) | Ocular shield for facilitating generation of visual evoked potentials (vep) | |
Alzahrani | The potential retinal blue hazard from dental examination lamps at different ages | |
Manual | Odyssey® 2.4 G |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |